Generate Biomedicines (GENB) Competitors

$14.53 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$14.53 0.00 (-0.03%)

As of 05/22/2026 07:57 PM Eastern

GENB vs. KYMR, PTGX, LNTH, TGTX, and RYTM

Should you buy Generate Biomedicines stock or one of its competitors? MarketBeat compares Generate Biomedicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Generate Biomedicines include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Lantheus (LNTH), TG Therapeutics (TGTX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

How does Generate Biomedicines compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Generate Biomedicines has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Generate Biomedicines' return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Generate Biomedicines	N/A	N/A	N/A

Generate Biomedicines has lower revenue, but higher earnings than Kymera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	165.51	-$311.35M	-$3.57	N/A
Generate Biomedicines	$30.30M	61.47	N/A	N/A	N/A

Kymera Therapeutics presently has a consensus target price of $118.10, indicating a potential upside of 49.70%. Generate Biomedicines has a consensus target price of $25.40, indicating a potential upside of 74.81%. Given Generate Biomedicines' higher probable upside, analysts clearly believe Generate Biomedicines is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Kymera Therapeutics had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 2 mentions for Kymera Therapeutics and 1 mentions for Generate Biomedicines. Kymera Therapeutics' average media sentiment score of 0.84 beat Generate Biomedicines' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kymera Therapeutics beats Generate Biomedicines on 7 of the 11 factors compared between the two stocks.

How does Generate Biomedicines compare to Protagonist Therapeutics?

Generate Biomedicines (NASDAQ:GENB) and Protagonist Therapeutics (NASDAQ:PTGX) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

In the previous week, Protagonist Therapeutics had 7 more articles in the media than Generate Biomedicines. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 1 mentions for Generate Biomedicines. Protagonist Therapeutics' average media sentiment score of 0.67 beat Generate Biomedicines' score of 0.00 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Generate Biomedicines has higher earnings, but lower revenue than Protagonist Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	61.47	N/A	N/A	N/A
Protagonist Therapeutics	$46.02M	138.61	-$130.15M	-$1.81	N/A

Generate Biomedicines has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Generate Biomedicines' return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

Generate Biomedicines currently has a consensus price target of $25.40, suggesting a potential upside of 74.81%. Protagonist Therapeutics has a consensus price target of $115.21, suggesting a potential upside of 16.16%. Given Generate Biomedicines' higher probable upside, equities research analysts plainly believe Generate Biomedicines is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Protagonist Therapeutics beats Generate Biomedicines on 9 of the 13 factors compared between the two stocks.

How does Generate Biomedicines compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, Lantheus had 4 more articles in the media than Generate Biomedicines. MarketBeat recorded 5 mentions for Lantheus and 1 mentions for Generate Biomedicines. Lantheus' average media sentiment score of 0.28 beat Generate Biomedicines' score of 0.00 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Lantheus shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lantheus currently has a consensus target price of $99.71, suggesting a potential downside of 3.19%. Generate Biomedicines has a consensus target price of $25.40, suggesting a potential upside of 74.81%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, analysts clearly believe Generate Biomedicines is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Lantheus has a net margin of 18.05% compared to Generate Biomedicines' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Generate Biomedicines	N/A	N/A	N/A

Lantheus has higher revenue and earnings than Generate Biomedicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.35	$233.56M	$4.15	24.82
Generate Biomedicines	$30.30M	61.47	N/A	N/A	N/A

Summary

Lantheus beats Generate Biomedicines on 9 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, TG Therapeutics had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 3 mentions for TG Therapeutics and 1 mentions for Generate Biomedicines. TG Therapeutics' average media sentiment score of 0.64 beat Generate Biomedicines' score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.6% of TG Therapeutics shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Generate Biomedicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.65	$447.18M	$2.86	13.59
Generate Biomedicines	$30.30M	61.47	N/A	N/A	N/A

TG Therapeutics has a net margin of 65.95% compared to Generate Biomedicines' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Generate Biomedicines	N/A	N/A	N/A

TG Therapeutics presently has a consensus price target of $52.50, suggesting a potential upside of 35.07%. Generate Biomedicines has a consensus price target of $25.40, suggesting a potential upside of 74.81%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, analysts plainly believe Generate Biomedicines is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

TG Therapeutics beats Generate Biomedicines on 9 of the 13 factors compared between the two stocks.

How does Generate Biomedicines compare to Rhythm Pharmaceuticals?

Generate Biomedicines (NASDAQ:GENB) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Generate Biomedicines and Generate Biomedicines both had 1 articles in the media. Generate Biomedicines' average media sentiment score of 0.00 equaled Rhythm Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines presently has a consensus target price of $25.40, suggesting a potential upside of 74.81%. Rhythm Pharmaceuticals has a consensus target price of $131.81, suggesting a potential upside of 50.06%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, equities research analysts plainly believe Generate Biomedicines is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84

Generate Biomedicines has higher earnings, but lower revenue than Rhythm Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	61.47	N/A	N/A	N/A
Rhythm Pharmaceuticals	$189.76M	31.72	-$196.54M	-$3.13	N/A

Generate Biomedicines has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Generate Biomedicines' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Summary

Generate Biomedicines beats Rhythm Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Generate Biomedicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENB vs. The Competition

Export

Metric	Generate Biomedicines	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.86B	$2.95B	$4.26B	$12.34B
Dividend Yield	N/A	15.26%	5.93%	5.28%
P/E Ratio	N/A	12.88	18.40	22.89
Price / Sales	61.47	1,866.35	180.55	86.28
Price / Cash	N/A	27.64	55.68	56.67
Price / Book	N/A	6.13	34.85	7.14
Net Income	N/A	-$42.06M	$112.32M	$335.98M
7 Day Performance	11.68%	0.99%	2.55%	3.56%
1 Month Performance	13.52%	1.57%	3.54%	2.54%
1 Year Performance	N/A	18.73%	15.79%	35.05%

Generate Biomedicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENB Generate Biomedicines	N/A	$14.53 flat	$25.40 +74.8%	N/A	$1.86B	$30.30M	N/A	312
KYMR Kymera Therapeutics	2.5817 of 5 stars	$78.39 -1.6%	$118.10 +50.7%	+167.5%	$6.46B	$39.21M	N/A	170
PTGX Protagonist Therapeutics	2.7621 of 5 stars	$99.15 -1.6%	$113.69 +14.7%	+117.2%	$6.38B	$46.02M	N/A	120
LNTH Lantheus	2.0639 of 5 stars	$93.74 +0.7%	$99.71 +6.4%	+39.5%	$6.12B	$1.54B	22.64	1,193	Gap Down
TGTX TG Therapeutics	4.3474 of 5 stars	$39.64 +0.4%	$52.50 +32.4%	+12.4%	$6.07B	$616.29M	13.86	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GENB) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Generate Biomedicines (GENB) Competitors

GENB vs. KYMR, PTGX, LNTH, TGTX, and RYTM

How does Generate Biomedicines compare to Kymera Therapeutics?

Summary

How does Generate Biomedicines compare to Protagonist Therapeutics?

Summary

How does Generate Biomedicines compare to Lantheus?

Summary

How does Generate Biomedicines compare to TG Therapeutics?

Summary

How does Generate Biomedicines compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Generate Biomedicines (GENB) Competitors

GENB vs. KYMR, PTGX, LNTH, TGTX, and RYTM

How does Generate Biomedicines compare to Kymera Therapeutics?

Is KYMR or GENB more profitable?

Which has preferable earnings & valuation, KYMR or GENB?

Do analysts prefer KYMR or GENB?

Does the media favor KYMR or GENB?

Summary

How does Generate Biomedicines compare to Protagonist Therapeutics?

Does the media favor GENB or PTGX?

Do insiders & institutionals hold more shares of GENB or PTGX?

Which has better earnings and valuation, GENB or PTGX?

Is GENB or PTGX more profitable?

Do analysts recommend GENB or PTGX?

Summary

How does Generate Biomedicines compare to Lantheus?

Does the media favor LNTH or GENB?

Do institutionals and insiders hold more shares of LNTH or GENB?

Do analysts rate LNTH or GENB?

Is LNTH or GENB more profitable?

Which has better earnings & valuation, LNTH or GENB?

Summary

How does Generate Biomedicines compare to TG Therapeutics?

Does the media prefer TGTX or GENB?

Do insiders and institutionals hold more shares of TGTX or GENB?

Which has preferable valuation & earnings, TGTX or GENB?

Is TGTX or GENB more profitable?

Do analysts rate TGTX or GENB?

Summary

How does Generate Biomedicines compare to Rhythm Pharmaceuticals?

Does the media refer more to GENB or RYTM?

Do analysts rate GENB or RYTM?

Which has stronger valuation & earnings, GENB or RYTM?

Is GENB or RYTM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools